This article was originally published in The Gold Sheet
Executive SummaryIt’s time to comment on ICH Q11
You may also be interested in...
Regulators in the U.S. and Europe are a little closer to harmonizing their reviews of new drug applications containing QbD elements under a joint review program. Areas of agreement include what is meant by QTPP and criticality, while areas of disagreement include NIR methods and design space development.